A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter H.M. Kim
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors H.M. Kim1, K.J. Lee2, S.W. Yi3, J.H. Lee1, S. Bang4, S.Y. Song5, S.W. Park6
  • 1Yonsei University Wonju College of Medicine, Wonju, Republic of Korea, /
  • 2Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea, /
  • 3Yong-in Severance Hospital, Seoul, Republic of Korea, /
  • 4Yonsei University, Seoul, Republic of Korea, /
  • 5Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, /
  • 6Yonsei University College of Medicine, Seoul, Republic of Korea, /

Abstract

Gemcitabine and cisplatin chemotherapy are standard treatment for patients with advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of gemcitabine and cisplatin based concurrent chemoradiotherapy in patients with locally advanced biliary tract cancer.